Antineoplastic AgentsChemotherapy, AdjuvantDrug UsersAntineoplastic Combined Chemotherapy ProtocolsSubstance-Related DisordersSubstance Abuse, IntravenousMedical OncologySEER ProgramBreast NeoplasmsDoxorubicinNeoplasm StagingDrug Screening Assays, AntitumorCell Line, TumorNeoplasmsRisk-TakingCisplatinTreatment OutcomeRadiation DosageRadiation, IonizingDrug Resistance, NeoplasmRadiation InjuriesHIV InfectionsAntineoplastic Agents, PhytogenicApoptosisAge FactorsCombined Modality TherapyAntibiotics, AntineoplasticEtoposideUnited StatesDose-Response Relationship, RadiationRadiation ToleranceCell SurvivalPaclitaxelCohort StudiesDrug Delivery SystemsRadiationRetrospective StudiesTumor Cells, CulturedCyclophosphamideCamptothecinXenograft Model Antitumor AssaysDrug CarriersRadiation ProtectionMice, NudeDose-Response Relationship, DrugRadiation MonitoringLung NeoplasmsCell ProliferationDrug Resistance, MultipleP-GlycoproteinAntimetabolites, AntineoplasticEllipticinesTime FactorsDrug SynergismDNA DamageOrganoplatinum CompoundsVinblastineInhibitory Concentration 50Antineoplastic Agents, AlkylatingMethotrexateBleomycinDaunorubicinDrug DesignMolecular StructureDisease-Free SurvivalDrug Administration ScheduleCell CycleRadiotherapyMitomycinSurvival AnalysisNeoadjuvant TherapyTaxoidsPlatinumCarboplatinPrognosisGene Expression Regulation, NeoplasticMitoxantroneRadiation-Sensitizing AgentsDeoxycytidineColonic NeoplasmsDNA Topoisomerases, Type IIDrug Evaluation, PreclinicalAdenocarcinomaRadiation OncologyEnzyme InhibitorsProdrugsClinical Trials as TopicSurvival RateTopoisomerase I InhibitorsGamma RaysAnthracyclinesDrug ResistanceOvarian NeoplasmsTumor Suppressor Protein p53NanoparticlesRadiotherapy DosageBrain NeoplasmsNanomedicineDrug DiscoveryMolecular Targeted Therapy